Category: Federal Forum Posters
Purpose: Cardiovascular diseases (CVD) are currently one of the major causes of disability and mortality in both economically well-developed as well as developing countries. The past years have witnessed major strides in the prevention of CVDs through modification of its causes. The most dramatic advance has been the demonstration that aggressive medical therapy will substantially reduce the likelihood of recurrent major coronary syndromes in patients with established CVD. The purpose of this study is to predict the incidence of CVD event by evaluating risk factors using QRISK and ASCVD risk assessment tools.
Methods: Prospective observational study conducted in intensive care unit (ICU), medical wards, surgical wards, and high intensive care unit (HICU) of tertiary-care hospital in India for 6 months. The required data was collected in form case sheets, treatment chart, lab master, the physical examination of the medication with patient is also verified. A questionnaire was used to gather information from patients. The age, sex, social status, laboratory data, weight, height, Blood Pressure (BP), family history and therapeutic management were recorded. The data was introduced to QRISK and ASCVD risk score calculators and the risk for development of CVD in each patient was determined and risk score was observed for each risk factor in the study sample. QRISK and ASCVD risk assessment tools, are among a number of scoring systems used to determine an individual's chances of developing cardiovascular disease by giving an estimate of the probability that a person will develop cardiovascular disease within a specified amount of time, usually 10 years. Results have altogether, 257 cases analyzed. QRISK and ASCVD risk scores were used to classify individuals according to Low, Moderate and High risk factor for developing CVD in the next few years of the individual’s life.
Results: As per QRISK and ASCVD scales, the percentage was respectively 31 percent (n equals 80) as Low risk, 32 percent (n equals 82) as Moderate risk, 37 percent (n equals 95) as High risk for ASCVD and 24 percent (n equals 62) as Low risk, 28 percent (n equals 72) as Moderate risk, 48 percent (n equals 123) as High risk for QRISK. Risk scores were compared for each risk factors using QRISK and ASCVD risk tool assessments. When compared according to their Blood Pressure, out of 44 patients with Stage 2 BP had high risk. 40 percent (n equels18) of the individual had High risk score for developing CVD events. Obese individuals were 13 percent (n equals 33) among sample and all of them had high risk according to QRISK and ASCVD. Smokers had higher risk according to QRISK than Non-Smokers with 40 percent (n equals 29) high risk score. Non-Diabetic patients were having lower risk according to ASCVD and QRISK than Diabetics with 67 percent (n equals 23) out of 46 of Non-Diabetic having low risk according to ASCVD and 50 percent (n equals 17) according to QRISK.
Conclusion: Risk of developing CVD event was predicted clinically QRISK and ASCVD risk assessment tools, which are among a number of scoring systems used to determine an individual's chances of developing cardiovascular disease by giving an estimate of the probability that a person will develop CVD within a specified amount of time, usually 10 years. Risk factor assessment tools can be conveniently used to assess general CVD risk and risk of individual CVD events (coronary, cerebrovascular, peripheral arterial disease and heart failure). The estimated absolute CVD event rates can be used to quantify risk and to guide preventive care.
Mitra Bakhshesh– Pharm.D. Intern, Karnataka College of Pharmacy, Bangalore, Karnataka, India